

IN THE CLAIMS:

Please amend claim 31, as shown below in the detailed listing of all claims which are, or were, in the application:

Claims 1-30 (canceled).

31. (Currently amended) A method for treatment of a local inflammatory disease or disorder, comprising

formulating administering a pharmaceutical composition to a person or animal in need thereof, said pharmaceutical composition consisting essentially of an active substance, said active substance consisting of a pharmaceutically acceptable agent or salt thereof capable of acidifying cell cytoplasm, said agent being an acid having a dissociation constant, expressed as its negative logarithm pKa, in the range of 6.7 to 7.4,

adjusting said pharmaceutical composition to having a pH range in the range of 6.1 to 7.0, and

~~administering said pharmaceutical composition to a person or animal in need thereof,~~

wherein the agent comprises an organic acid having a heterocyclic ring selected from the group consisting of imidazole,

thiazole, thiophene, furan, oxazole, triazole, tetrazole, pyrazole, pyridine, pyrimidine and triazine.

32. (Previously presented) The method of claim 31, further comprising

inhibiting a reaction involving activation of cells of the innate immune system.

33. (Previously presented) The method of claim 32, wherein said reaction is a member of the group consisting of contact hypersensitivity reactions, delayed type hypersensitivity reactions, acute graft rejection, psoriasis, dermatitis, periodontitis, mastitis, and vasculitis.

34. (Previously presented) The method of claim 31, wherein the agent is administered systemically or locally.

35. (Previously presented) The method of claim 34, where said agent is administered locally.

36. (Previously presented) The method according to claim 31, wherein the agent is *cis*-urocanic acid.